Nintedanib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Nintedanib and local guidelines before prescribing.
Mechanism
Tyrosine kinase inhibitor targeting FGFR, PDGFR, VEGFR.
Uses
Idiopathic pulmonary fibrosis, progressive fibrosing ILD, systemic sclerosis ILD.
Dosing
- Nintedanib IPF, progressive pulmonary fibrosis | 150 mg twice daily. IPF FVC 50–80% (TA379) and above 80% (TA864); progressive pulmonary fibrosis (TA747). Diarrhoea, raised LFTs; caution with anticoagulants.
Respiratory: Interstitial Lung Disease
Side effects
Diarrhoea, nausea, raised LFT, weight loss, bleeding risk, thromboembolism.
Interactions
P-gp and CYP3A4 inhibitors or inducers alter levels; anticoagulants.
Contraindications and cautions
Moderate to severe liver impairment, bleeding risk
Monitoring
LFT, weight, GI symptoms
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in moderate to severe liver impairment
Overdose and reversal
Supportive
Special advice
Take with food; manage diarrhoea early with loperamide; check LFT monthly for first 3 months.
More from the textbook: uses, cautions and other points
- Pirfenidone and nintedanib - slow the decline in lung function (FVC) in idiopathic pulmonary fibrosis ; nintedanib is also used in progressive pulmonary fibrosis from other causes (NICE TAs). They don't reverse existing fibrosis.
Respiratory: Anatomy, Physiology and Pharmacology - Nintedanib (tyrosine kinase inhibitor) - side effects: diarrhoea (very common - loperamide), nausea, raised LFTs; bleeding risk (care with anticoagulants); teratogenic.
Respiratory: Anatomy, Physiology and Pharmacology - Pirfenidone side effects: photosensitivity rash , nausea, weight loss. Nintedanib side effects: diarrhoea , raised LFTs.
Respiratory: Interstitial Lung Disease - Pirfenidone / nintedanib | Antifibrotics for IPF; photosensitivity / diarrhoea; LFTs.
Respiratory: Anatomy, Physiology and Pharmacology - NICE TAs: Biologics for severe asthma; pirfenidone and nintedanib for IPF and progressive fibrosis; CFTR modulators
Respiratory: Anatomy, Physiology and Pharmacology - Pirfenidone or nintedanib for people with FVC 50–80% predicted (NICE TA504, TA379).
Respiratory: Interstitial Lung Disease - Nintedanib is now also recommended when FVC is above 80% (NICE TA864).
Respiratory: Interstitial Lung Disease - Treatment: Nintedanib slows FVC decline (NICE TA747), alongside treatment of the underlying condition.
Respiratory: Interstitial Lung Disease
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (4 mentions)
- Respiratory: Interstitial Lung Disease (11 mentions)
- Rheumatology: Connective tissue diseases (1 mention)
- Rheumatology: Inflammatory arthritis (1 mention)
- Integrated respiratory chapter (11 mentions)
- 0225 (1 mention)